Creatine phosphate: Pharmacological and clinical perspectives

Advances in Therapy

Volumn 29, Issue 2, 2012, Pages 99-123

  Strumia, Ettore ^a   Pelliccia, Francesco ^b   D'Ambrosio, Giuseppe ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c International Medical Affairs Department   (Italy)

Author keywords

cardiac surgery; cardioplegia; congestive heart failure; creatine phosphate or phosphocreatine; CrP; myocardial ischemia; skeletal muscle rehabilitation and performance

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE; CREATINE PHOSPHATE; DIGITALIS; DIURETIC AGENT; GLYCEROPHOSPHOLIPID; LYSOPHOSPHOGLYCERIDE; NITRATE; PHOSPHOLIPID; PLACEBO; UNCLASSIFIED DRUG;

BRAIN ISCHEMIA; CELL ENERGY; CELL LEVEL; CELL MEMBRANE; CLINICAL RESEARCH; DRUG TARGETING; EXPERIMENT; HEART ARRHYTHMIA; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART SURGERY; HUMAN; HYPOXIA; METABOLIC DISORDER; MUSCLE METABOLISM; MYOPATHY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SKELETAL MUSCLE; SKELETAL MUSCLE HYPOTONOTROPHY; STATIC ELECTRICITY; WORK;

ADENOSINE TRIPHOSPHATE; CARDIOTONIC AGENTS; ENERGY METABOLISM; HEART; HUMANS; MUSCLE CONTRACTION; MUSCLE, SKELETAL; MYOCARDIUM; PHOSPHOCREATINE;

EID: 84857899587     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0091-4     Document Type: Review

References (107)

1. Walker JB. Creatine: biosynthesis, regulation, and function. Adv Enzymol Relat Areas Mol Biol. 1979;50:117-242.
2. Ennor AH, Morrison JF. Biochemistry of the phosphagens and related guanidines. Physiol Rev. 1958;38:631-674.
3. Bessman SP, Geiger PJ. Transport of energy in muscle: the phosphorylcreatine shuttle. Science. 1981;211:448-452. (Pubitemid 11145312)
4. Bessman SP, Mohan C. Phosphocreatine, exercise, protein synthesis, and insulin. In: PP De Deyn, B, Marescau, V. Stalon an IA Qureshi, eds. Guanidino Compounds in Biology and Medicine. London: John Libbey and Company; 1992:181-186.
5. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res. 2004;95:135-145. (Pubitemid 38988679)
6. Taegtmeyer H, Wilson CR, Razeghi P, Sharma S. Metabolic energetics and genetics in the heart. Ann N Y Acad Sci. 2005;1047:208-218. (Pubitemid 41123841)
7. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res. 2009;81:412-419.
8. Saks VA, Ventura-Clapier R, Huchua ZA, Preobrazhensky AN, Emelin IV. A creatine kinase in regulation of heart function and metabolism. I. Further evidence for compartmentation of adenine nucleotides in cardiac myofibrillar and sarcolemmal coupled ATPase-creatine kinase systems. Biochim Biophys Acta. 1984;803:254-264. (Pubitemid 14138201)
9. Carpenter CL, Mohan C, Bessman SP. Inhibition of protein and lipid synthesis in muscle by 2,4-dinitrofluorobenzene, an inhibitor of creatine phosphokinase. Biochem Biophys Res Commun. 1983; 111:884-889. (Pubitemid 13081834)
10. Hearse DJ. Oxygen deprivation and early myocardial contractile failure: a reassessment of the possible role of adenosine triphosphate. Am J Cardiol. 1979;44:1115-1121. (Pubitemid 10205776)
11. Whitman GJ, Kieval RS, Seeholzer S, et al. Recovery of left ventricular function after graded cardiac ischemia as predicted by myocardial P-31 nuclear magnetic resonance. Surgery. 1985;97:428-435. (Pubitemid 15074395)
12. Pool PE, Spann JF Jr, Buccino RA, Sonnenblick EH, Braunwald E. Myocardial high energy phosphate stores in cardiac hypertrophy and heart failure. Circ Res. 1967;21:365-375.
13. Ye Y, Gong G, Ochiai K, Liu J, Zhang J. High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation. 2001;103:1570-1576. (Pubitemid 32226267)
14. Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith G. Regional myocardial metabolism of high energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med. 1990;323:1593-1600.
15. Yabe T, Mitsunami K, Okada M, et al. Detection of myocardial ischemia by 31P magnetic resonance spectroscopy during handgrip exercise. Circulation. 1994;89:1709-1716.
16. Yabe T, Mitsunami K, Inubushi T, Kinoshita M. Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. Circulation. 1995;92:15-23.
17. 31P magnetic resonance spectroscopy. Lancet. 1991;338:973-976.
18. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J. 1991;122:795-801.
19. Neubauer S, Krahe T, Schindler R, et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation. 1992;86:1810-1818.
20. Naveri HK, Leinonen H, Kiilavuori K, Härkönen M. Skeletal muscle lactate accumulation and creatine phosphate depletion during heavy exercise in congestive heart failure. Cause of limited exercise capacity? Eur Heart J. 1997;18:1937-1945. (Pubitemid 27526125)
21. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190-2196. (Pubitemid 27425822)
22. Chida K, Otani H, Kohzuki M, et al. The relationship between plasma BNP level and the myocardial phosphocreatine/adenosine triphosphate ratio determined by phosphorus-31 magnetic resonance spectroscopy in patients with dilated cardiomyopathy. Cardiology. 2006;106:132-136. (Pubitemid 44474980)
23. Starling RC, Hammer DF, Altschuld RA. Human myocardial ATP content and in vivo contractile function. Mol Cell Biochem. 1998;180:171-177. (Pubitemid 28118817)
24. Nascimben L, Ingwall JS, Pauletto P, et al. Creatine kinase system in failing and nonfailing human myocardium. Circulation. 1996;94:1894-1901. (Pubitemid 26349302)
25. Tian R, Ingwall JS. The molecular energetics of the failing heart from animal models-small animal models. Heart Failure Rev. 1999;4:235-253.
26. Zhang J, Bache RJ. The molecular energetics of the failing heart from animal models-large animal models. Heart Failure Rev. 1999;4:255-267. (Pubitemid 30153585)
27. Ingwall JS, Kramer MF, Fifer MA, et al. The creatine kinase system in normal and diseased human myocardium. N Engl J Med. 1985;313:1050-1054. (Pubitemid 16243332)
28. Katz AM. Is the failing heart energy depleted? Cardiol Clin. 1998;16:633-644, viii. (Pubitemid 28509447)
29. Nakae I, Mitsunami K, Omura T, et al. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol. 2003;42:1587-1593. (Pubitemid 37378437)
30. van Bilsen M, Smeets PJ, Gilde AJ, van der Vusse GJ. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardiovasc Res. 2004;61:218-226. (Pubitemid 38091762)
31. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med. 2007;356:1140-1151. (Pubitemid 46425598)
32. Editorial: Skeletal muscle in heart failure. Lancet. 1992;340:1383-1384.
33. Drexler H, Münzel T, Riede U, Just H. Adaptive changes in the periphery and their therapeutic consequences. Am J Cardiol. 1991;67:29C-34C; discussion 34C-35C.
34. Drexler H. Skeletal muscle failure in heart failure. Circulation. 1992;85:1364-1373.
35. Drexler H, Coats AJ. Explaining fatigue in congestive heart failure. Annu Rev Med. 1996;47:241-256. (Pubitemid 26138889)
36. Massie BM, Conway M, Rajagopalan B, et al. Skeletal muscle metabolism during exercise under ischemic conditions in congestive heart failure. Evidence for abnormalities unrelated to blood flow. Circulation. 1988;78:320-326.
37. Mancini DM, Walter G, Reichek N, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation. 1992;85:1364-1373.
38. Mancini DM, Wilson JR, Bolinger L, et al. In vivo magnetic resonance spectroscopy measurement of deoxymyoglobin during exercise in patients with heart failure. Demonstration of abnormal muscle metabolism despite adequate oxygenation. Circulation. 1994;90:500-508. (Pubitemid 24203718)
39. Lunde PK, Sjaastad I, Schiøtz Thorud HM, Sejersted OM. Skeletal muscle disorders in heart failure. Acta Physiol Scand. 2001;171:277-294. (Pubitemid 32823795)
40. Parratt JR, Marshall RJ. The response of isolated cardiac muscle to acute anoxia: protective effect of adenosine triphosphate and creatine phosphate. J Pharm Pharmacol. 1974;26:427-433.
41. Marshall RJ, Parratt JR. Reduction in ventricular arrhythmias following acute coronary artery ligation in the dog after the administration of creatine phosphate. Naunyn Schmiedeberg's Arch Pharmacol. 1974;281:437-441.
42. Fagbemi O, Kane KA, Parratt JR. Creatine phosphate suppresses ventricular arrhythmias resulting from coronary artery ligation. J Cardiovasc Pharmacol. 1982;4:53-58. (Pubitemid 12210531)
43. Rosenshtraukh LV, Saks VA, Anyukhovsky EP, Beloshapko GG, Yushmanova AV. The antiarrhythmic action of creatine phosphate in acute myocardial ischemia. Biochem Med. 1985;34:120-128. (Pubitemid 15045305)
44. Hearse DJ, Tanaka K, Crome R, Manning AS. Creatine phosphate and protection against reperfusion-induced arrhythmias in the rat heart. Eur J Pharmacol. 1986;131:21-30. (Pubitemid 17217996)
45. Sharov VG, Afonskaya NI, Ruda MY, et al. Protection of ischemic myocardium by exogenous phosphocreatine: Pharmacokinetics of phosphocreatine, reduction of infarct size, stabilization of sarcolemma of ischemic cardiomyocytes and antithrombotic action. Biochem Med Metab Biol. 1986;35:101-114. (Pubitemid 16100332)
46. Woo YJ, Grand TJ, Zentko S, et al. Creatine phosphate administration preserves myocardial function in a model of off-pump coronary revascularization. J Cardiovasc Surg. 2005;46:297-305.
47. Robinson LA, Braimbridge MV, Hearse DJ. Creatine phosphate: an additive myocardial protective and antiarrhythmic agent in cardioplegia. J Thorac Cardiovasc Surg. 1984;87:190-200. (Pubitemid 14190010)
48. Sharov VG, Saks VA, Kupriyanov VV, et al. Protection of ischemic myocardium by exogenous creatine phosphate: morphologic and phosphorus 31-nuclear magnetic resonance studies. J Thorac Cardiovasc Surg. 1987;94:749-761. (Pubitemid 17163560)
49. Thelin S, Hultman J, Ronquist G, et al. Improved myocardial protection by creatine phosphate in cardioplegic solution. An in vivo study in the pig during normothermic ischemia. Thorac Cardiovasc Surg. 1987;35:137-142. (Pubitemid 17096500)
50. Down WH, Chasseaud LF, Ballard SA. The effect of intravenously administered phosphocreatine on ATP and phosphocreatine concentrations in the cardiac muscle of the rat. Arzneimittelforschung. 1983;33:552-554. (Pubitemid 13161976)
51. Breccia A, Fini A, Girotti S, Gattavecchia E. Intracellular distribution of double-labelled creatine phosphate in the rabbit myocardium. Curr Ther Res. 1985;37:1205-1215. (Pubitemid 15090203)
52. Preobrazhensky AN, Javadov SA, Saks VA. Study of the hypothetical mechanism of protective effect of phosphocreatine on ischemic myocardium. Biochimia. 1986;51:675-683. (Pubitemid 16053010)
53. Jacobus WE. Respiratory control and the integration of heart high-energy phosphate metabolism by mithocondrial creatine kinase. Annu Rev Physiol. 1985;47:707-725. (Pubitemid 15142407)
54. Saks VA, Strumia E. Phosphocreatine: Molecular and cellular aspects of the mechanism of cardioprotective action. Curr Ther Res. 1993;53:565-598. (Pubitemid 23242223)
55. Ronca-Testoni A, Raggi A, Ronca G. Muscle AMP aminohydrolase. Comparative study on the regulatory properties of skeletal muscle enzyme from various species. Biochim Biophys Acta. 1970;198:101-112.
56. Saks VA, Javadov SA, Pozin E, Preobrazhensky AN. Biochemical basis of the protective action of phosphocreatine on the ischemic myocardium. In: Saks VA, Bobkov, Strumia E, eds. Proceedings of the Symposium "Creatine phosphate-biochemistry, pharmacology and clinical efficiency" Baku, October 1986. Torino: Edizioni Minerva Medica; 1987:95-111.
57. Rubio R, Belardinelli L, Thompson CI, Berne RM. Cardiac adenosine: Electrophysiological effects, possible significance in cell function and mechanism controlling its release. In: Baer HP, Drummond GI, eds. Physiological and Regulatory Functions of Adenosine and Adenine Nucleotides. New York: Raven Press; 1979:167-183.
58. Ronca G, Ronca-Testoni S, Conte A, et al. Creatine phosphate and protection from peroxidative damage. Proceedings of the International Meeting "Cardioprotection with phosphocreatine in cardiology and cardiac surgery" IRCCS, Policlinical S.Matteo, Università degli Studi, Pavia, Italy, April 1989:61-71.
59. Zucchi R, Poddighe R, Limbruno U, et al. Protection of isolated rat heart from oxidative stress by exogenous phosphocreatine. J Mol Cell Cardiol. 1989;21:67-73. (Pubitemid 19078694)
60. Konorev EA, Sharov VG, Saks VA. Improvement in contractile recovery of isolated rat heart after cardioplegic ischemic arrest with endogenous phosphocreatine: Involvement of antiperoxidative effect. Cardiovasc Res. 1991;25:164-171.
61. Corr PB, Witkowski FX, Sobel BE. Mechanism contributing to malignant dysrhythmias induced by ischemia in the cat. J Clin Invest. 1978;61:109-119. (Pubitemid 8262335)
62. Sobel BE, Corr PB. Accumulation of lysophosphoglycerides with arrhythmogenic properties in ischemic myocardium. J Clin Invest. 1978;62:546-553. (Pubitemid 9006422)
63. Saks VA, Kapelko VI, Ruda MY, Semenovski ML, Strumia E. Phosphocreatine as effective drug in clinical cardiology. In: De Deyn PP, Marescau B, Stalon V, Qureshi IA, eds. Guanidino Compounds in Biology and Medicine. London: John Libbey &Company; 1992:239-248.
64. Guzun R, Timohhina N, Tepp K, et al. Systems bioenergetics of creatine kinase networks: physiological roles of creatine and phosphocreatine in regulation of cardiac cell function. Amino Acids. 2011;40:1333-1348.
65. Hearse DJ, Brainbridge MV, Jynge P. Protection of the Ischemic Myocardium: Cardioplegia. New York: Raven Press; 1981:151-156.
66. Semenovsky ML, Shumakov VI, Sharov VG, et al. Protection of ischemic myocardium by exogenous creatine phosphate. II. Clinical, ultrastructural and biochemical evaluations. J Thorac Cardiovasc Surg. 1987;94:762-769. (Pubitemid 17163561)
67. D'Alessandro LC, Cini R, Pucci A, et al. Protezione miocardica: uso del creatin fosfato addizionato alla soluzione cardioplegica. Heart Surgery 1987, 2nd International Symposium on Cardiac Surgery, Roma 1987, Casa Editrice Internazionale; 179-192.
68. Chambers DJ, Braimbridge MV, Kosker S, et al. Creatine phosphate (Neoton) as an additive to St. Thomas' Hospital cardioplegic solution (Plegisol). Results of a clinical study. Eur J Cardiothor Surg. 1991;5:74-81.
69. Chambers DJ, Haire K, Morley N, et al. St. Thomas' Hospital cardioplegia: enhanced protection with exogenous creatine phosphate. Ann Thor Surg. 1996;61:67-75. (Pubitemid 26053492)
70. Mastroroberto P, Di Tommaso L, Chello M, et al. Creatine phosphate protection of the ischemic myocardium during cardiac surgery. Curr Ther Res. 1992;51:37-45.
71. Pauletto P, Nascimben L, De Ros S, et al. Prevention of arrhythmias and changes in myocardial enzyme release with creatine phosphate in patients undergoing coronary artery by-pass. J Mol Cell Cardiol. 1993;25(Suppl. 3):109 (Abstract).
72. Pastoris O, Dossena M, Vercesi L, et al. Biochemical changes induced in the myocardial cell during cardioplegic arrest supplemented with creatine phosphate. J Cardiothorac Vasc Anesth. 1991;5:475-480.
73. Pagani L, Musiani A. The use of systemic phosphocreatine in heart surgery. Minerva Anestesiol. 1992;58:199-205.
74. Cisowski M, Bochenek A, Kucewicz E, et al. The use of exogenous creatine phosphate for myocardial protection in patients undergoing coronary artery bypass surgery. A clinical assessment. J Cardiovasc Surg. 1996;37:75-80. (Pubitemid 126701091)
75. Thorelius J, Thelin S, Ronquist G, Halden E, Hansson HE. Biochemical and functional effects of creatine phosphate in cardioplegic solution during aortic valve surgery. A clinical study. Thorac Cardiovasc Surg. 1992;40:10-13.
76. Cossolini M, Sonzogni V, Di Dedda G, et al. Paediatric cold heart surgery: experience with creatine phosphate added to cardioplegic solution. In: D'Alessandro LC, ed. Heart Surgery. Roma: Casa Editrice Scientifica Internazionale; 1993:442-443.
77. Ruda MY, Samarenko MB, Afonskaya NI, Saks VA. Reduction of ventricular arrhythmias by creatine phosphate in patients with acute myocardial infarction. Am Heart J. 1988;116:393-397.
78. Reimers B, Maddalena F, Cacciavilani L, et al. La fosfocreatina nell'infarto miocardico acuto: studio randomizzato multicentrico. Il Cuore. 1994;11:345-354.
79. Scattolin G, Gambino A, Bellotto F, et al. Phosphocreatine in acute myocardial infarction. In: Saks VA, Bobkov YG, Strumia E, eds. Proceeding of the Symposium "Creatine Phosphate: Biochemistry, Pharmacology and Clinical Efficiency", Baku, 6 October 1986. Torino: Minerva Medica; 1987;199-205.
80. Coraggio F, Spina M, Scarpato P. Analysis of creatine phosphate on the evolution of ischemic lesion in acute myocardial infarction. Farmaci Terapia. 1987;4:91-93.
81. Cini R, Stazi G, Giacopino F, et al. Creatinfosfato nella fase acuta dell'infarto miocardico. Risultati preliminari di uno studio clinico. Il Cuore. 1987;4:91-102.
82. Raisaro A, Bargiggia CS, Bertucci C, et al. Clinical evaluation of phosphocreatine effect during acute myocardial infarction: A multicenter study. Proceedings of the International Meeting "Cardioprotection with phosphocreatine in cardiology and cardiac surgery" IRCCS, Policlinico S. Matteo, Università degli studi, Pavia; 1989:139-147.
83. Camilova UK, Katsenovich RA, Kostco SZ. Combined use of creatine phosphate and nifedipine for treatment of patients with acute myocardial infarction. Curr Ther Res. 1991;50:591-598.
84. Iosseliani DG, Koledinsky AG, Kuchkina NV. Does intracoronary injection of phosphocreatine prevent myocardial reperfusion injury following angioplasty of infarct-related artery in acute-stage of myocardial infarction? J Intervent Cardiol. 2004;6:10-14.
85. Iosseliani DG, Koledinsky AG, Kuchkina NV. The possibility to limit reperfusion injury of cardiomyocytes using intracoronary cytoprotectors during endovascular reperfusion of the infarct-related artery. J Intervent Cardiol. 2006;11:10-16.
86. Smilari L, La Mela C, Santagati A, et al. Study of left ventricular function in ischemic cardiomyopathies before and after phosphocreatine infusion. Echocardiographic study. Curr Ther Res. 1987;41:557-567. (Pubitemid 17065338)
87. Ferraro S, Codella C, Palumbo F, et al. Hemodynamic effects of creatine phosphate in patients with congestive heart failure: a double-blind comparison trial versus placebo. Clin Cardiol. 1996;19:699-703. (Pubitemid 26296802)
88. Cafiero M, Strumia E, Pirone S, Pacileo S, Santoro R. Efficacia della creatina fosfato nel trattamento dei pazienti con insufficienza cardiaca, valutazione ecocardiografica dopo trattamento acuto e protratto. Clin Ter. 1994;144:321-328. (Pubitemid 24124900)
89. Strozzi C, Bagni B, Ferri A. Creatine phosphate in the treatment of chronic ischemic heart failure. Curr Ther Res. 1992;51:925-932.
90. Scattolin G, Gabellini A, Desideri A, et al. Diastolic function and creatine phosphate: an echocardiografic study. Curr Ther Res. 1993;54:562-571. (Pubitemid 23345935)
91. Gelfgat EB, Dalili IG, Shakhtakhtinskaya FN, Yagisarova NM, Shirinova EA. The effect of phosphocreatine on the tolerance of physical exercise in patients with ischemic heart disease. In: Saks VA, Bobkov YG, Strumia E, eds. Proceeding of the Symposium "Creatine Phosphate: Biochemistry, Pharmacology and Clinical Efficiency", Baku, 6 October 1986. Torino: Minerva Medica; 1987:270.
92. Grazioli I, Strumia E. Terapia con creatina fosfato nel paziente con insufficienza cardiaca in fase di scompenso: studio policentrico. G Ital Ric Clin Ter. 1989;10:39-45.
93. Grazioli I, Melzi G, Strumia E. Multicentre controlled study of creatine phosphate in the treatment of heart failure. Curr Ther Res. 1992;52:271-280.
94. Andreev NA, Andreeva TN, Bichkov IV. Effect of creatine phosphate in congestive heart failure. Curr Ther Res. 1992;51:649-660.
95. Galyautdinov GS, Saks VA, Kots Y, Vdovenko LG. Clinical application of creatine phosphate in congestive heart failure, evaluation of general clinical efficiency. Il Cuore. 1993;10:185-193. (Pubitemid 23202186)
96. Wang FR, Zheng X. Effects of phosphocreatine on plasma brain natriuretic peptide level and left ventricular function in patients with heart failure. Liaoning: Affiliated Hospital, Chinese Medicine University. Published at PJCCPVD, August 2008;16:29-31.
97. Yang W, Tang L. Clinical analysis on the treatment of pediatric myocarditis by neoton. Beijing Med J. 2001;23:19-20.
98. Dal Monte A, Leonardi LM, Figura F, et al. Effetti dell'apporto esogeno di fosfocreatina sulla potenza muscolare umana. Gazz Med Ital. 1976;135:1-11.
99. Tegazzin V, Rossi M, Schiavon M, et al. Indagine sulla performance di ciclisti trattati e non trattati con fosfocreatina. Biol Med. 1991;13:121-135.
100. Vorobiev DV, Vetrova EG, Larina IM, Popova IA, Grigoriev AI. Energy substrates, hormone responses and glucocorticoid binding in lymphocytes during intense physical exercise in humans following phosphocreatine administration. Eur J Appl Physiol Occup Physiol. 1996;74:534-540. (Pubitemid 26413565)
101. Satolli F, Marchesi G. Creatine phosphate in the rehabilitation of patients with muscle hypotonotrophy of the lower extremity. Curr Ther Res. 1989;46:67-73. (Pubitemid 19193329)
102. Agnese L, Tarello M, Grazioli I. Efficacia della creatina fosfato nel trattamento della ipotonotrofia da non uso della muscolatura scheletrica. Ort e Traum Oggi. 1992;12:107-113. (Pubitemid 23051100)
103. Pirola V, Pisani L, Teruzzi P. Valutazione del recupero del trofismo muscolare in pazienti anziani con frattura di femore trattati con creatina fosfato e fisiokinesiterapia. Clin Ter. 1991;139:115-119.
104. Weber P, Vlašicová Y, Lábrová R, Semrád B. Asset of creatine phosphate for cardiocerebral syndrome treatment in acute myocardial infarction in old age. Cas Lék Ces. 1992;134:53-56.
105. Skrivanek O, Kalvach P, Benetin J, et al. Creatine phosphate in the treatment of acute ischaemic stroke. Prakticky Lekar. 1995;75:7-8.
106. Bakala J, Kalita Z. SPECT findings in patients with acute stroke treated with NEOTON. Paper presented at: Proceedings of the "13th International Czech and Slovak Neurovascular Symposium"; June 8-9, 1995, Zlin, Czech Republic.
107. Zhang G, Luo W, Zheng J, He W. Clinical observation and blood gas changes after the treatment of neoton in neonates with moderate or severe hypoxic ischemic encephalopathy. Pediatr Emerg Med. 2004;11:397-398.